Ceftazidime-Avibactam Combination Therapy versus Monotherapy for the Treatment Carbapenem-Resistant Gram-Negative Bacterial Infections: A Retrospective Observational Study

References

• Jean SS, Harnod D, Hsueh PR. Global threat of carbapenem-resistant gram-negative bacteria. Front Cell Infect Microbiol. 2022;12:823684. doi:10.3389/fcimb.2022.823684
   PubMed Web of Science ®Google Scholar
• Babiker A, Clarke LG, Saul M, Gealey JA, Clancy CJ, Nguyen MH. Changing epidemiology and decreased mortality associated with carbapenem-resistant gram-negative bacteria, 2000–2017. Clin Infect Dis. 2021;73(11):e4521–e4530. doi:10.1093/cid/ciaa1464
   PubMed Web of Science ®Google Scholar
• Tangden T, Ramos MV, Felton TW, et al. The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med. 2017;43(7):1021–1032. doi:10.1007/s00134-017-4780-6
   PubMed Web of Science ®Google Scholar
• Doi Y, Bonomo RA, Hooper DC, et al. Gram-negative bacterial infections: research priorities, accomplishments, and future directions of the antibacterial resistance leadership group. Clin Infect Dis. 2017;64(suppl_1):S30–S35. doi:10.1093/cid/ciw829
   PubMed Web of Science ®Google Scholar
• Shein AMS, Hongsing P, Abe S, et al. Will there ever be cure for chronic, life-changing colistin-resistant Klebsiella pneumoniae in urinary tract infection? Front Med. 2021;8:806849. doi:10.3389/fmed.2021.806849
   Web of Science ®Google Scholar
• Shein AMS, Wannigama DL, Higgins PG, et al. High prevalence of mgrB-mediated colistin resistance among carbapenem-resistant Klebsiella pneumoniae is associated with biofilm formation, and can be overcome by colistin-EDTA combination therapy. Sci Rep. 2022;12(1):12939. doi:10.1038/s41598-022-17083-5
   PubMed Web of Science ®Google Scholar
• Shein AMS, Wannigama DL, Higgins PG, et al. Novel colistin-EDTA combination for successful eradication of colistin-resistant Klebsiella pneumoniae catheter-related biofilm infections. Sci Rep. 2021;11(1):21676. doi:10.1038/s41598-021-01052-5
   PubMed Web of Science ®Google Scholar
• Chen J, Liang Q, Ding S, et al. Ceftazidime-avibactam for the treatment of carbapenem-resistant pseudomonas aeruginosa infection in lung transplant recipients. Infect Drug Resist. 2023;16:2237–2246. doi:10.2147/IDR.S407515
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem-resistant Enterobacteriaceae infections. Clin Microbiol Infect. 2019;25(8):943–950. doi:10.1016/j.cmi.2019.04.013
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Q, Yin Y, et al. Epidemiology of carbapenem-resistant enterobacteriaceae infections: report from the China CRE network. Antimicrob Agents Chemother. 2018;62(2):2. doi:10.1128/AAC.01882-17
   Web of Science ®Google Scholar
• Shirley M. Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections. Drugs. 2018;78(6):675–692. doi:10.1007/s40265-018-0902-x
   PubMed Web of Science ®Google Scholar
• Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, Phase 3 program. Clin Infect Dis. 2016;62(11):1380–1389. doi:10.1093/cid/ciw133
   PubMed Web of Science ®Google Scholar
• Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomized, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18(3):285–295. doi:10.1016/S1473-3099(17)30747-8
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Raffaelli F, Giannella M, et al. Ceftazidime-Avibactam use for klebsiella pneumoniae carbapenemase-producing K. Pneumoniae infections: a retrospective observational multicenter study. Clin Infect Dis. 2021;73(9):1664–1676. doi:10.1093/cid/ciab176
   PubMed Web of Science ®Google Scholar
• Zhu X, Wang H, Guo K, et al. Chinese journal of integrated traditional and western medicine in intensive and critical care. Chin J TCM WM Crit Care. 2022;29(3):284–287.
   Google Scholar
• Zhen S, Wang H, Feng S. Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections. Infection. 2022;50(6):1409–1423. doi:10.1007/s15010-022-01876-x
   PubMed Web of Science ®Google Scholar
• Vena A, Giacobbe DR, Castaldo N, et al. Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant gram-negative bacteria other than carbapenem-resistant enterobacterales. Antibiotics. 2020;9(2):71. doi:10.3390/antibiotics9020071
   Web of Science ®Google Scholar
• Shein AMS, Wannigama DL, Hurst C, et al. Novel intranasal phage-CaEDTA-ceftazidime/avibactam triple combination therapy demonstrates remarkable efficacy in treating Pseudomonas aeruginosa lung infection. Biomed. Pharmacother. 2023;168:115793. doi:10.1016/j.biopha.2023.115793
   Web of Science ®Google Scholar
• Wannigama DL, Sithu Shein AM, Hurst C, et al. Ca-EDTA restores the activity of ceftazidime-avibactam or aztreonam against carbapenemase-producing Klebsiella pneumoniae infections. iScience. 2023;26(7):107215. doi:10.1016/j.isci.2023.107215
   PubMed Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022;75(2):187–212. doi:10.1093/cid/ciac268
   PubMed Web of Science ®Google Scholar
• Zheng G, Zhang J, Wang B, et al. Ceftazidime-avibactam in combination with in vitro non-susceptible antimicrobials versus ceftazidime-avibactam in monotherapy in critically ill patients with carbapenem-resistant klebsiella pneumoniae infection: a retrospective cohort study. Infect Dis Ther. 2021;10(3):1699–1713. doi:10.1007/s40121-021-00479-7
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of healthcare-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–332. doi:10.1016/j.ajic.2008.03.002
   PubMed Web of Science ®Google Scholar
• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–810. doi:10.1001/jama.2016.0287
   PubMed Web of Science ®Google Scholar
• Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707–710. doi:10.1007/BF01709751
   PubMed Web of Science ®Google Scholar
• Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–829. doi:10.1097/00003246-198510000-00009
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial- susceptibility testing; 2019, M100–M129.
   Google Scholar
• Alexander EL, Loutit J, Tumbarello M, et al. Carbapenem-resistant Enterobacteriaceae infections: results from a retrospective series and implications for the design of prospective clinical trials. Open Forum Infect Dis. 2017;4:ofx063.
   PubMed Web of Science ®Google Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58(4):2322–2328. doi:10.1128/AAC.02166-13
   PubMed Web of Science ®Google Scholar
• Tzouvelekis LS, Markogiannakis A, Piperaki E, et al. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2014;20(9):862–872. doi:10.1111/1469-0691.12697
   PubMed Web of Science ®Google Scholar
• Fiore M, Alfieri A, Di Franco S, et al. Ceftazidime-avibactam combination therapy compared to ceftazidime-avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: a systematic review and network meta-analysis. Antibiotics. 2020;9(7):388. doi:10.3390/antibiotics9070388
   Web of Science ®Google Scholar
• Balandin B, Ballesteros D, Pintado V, et al. Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients. Int J Antimicrob Agents. 2022;59(3):106536. doi:10.1016/j.ijantimicag.2022.106536
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019;68(3):355–364. doi:10.1093/cid/ciy492
   PubMed Web of Science ®Google Scholar
• Blot S, Antonelli M, Arvaniti K, et al.; Abdominal Sepsis Study (AbSeS) group on behalf of the Trials Group of the European Society of Intensive Care Medicine. Epidemiology of intra-abdominal infection and sepsis in critically ill patients: ”AbSeS”, a multinational observational cohort study and ESICM Trials Group Project. Intensive Care Med. 2019;45(12):1703–1717. doi:10.1007/s00134-019-05819-3
   PubMed Web of Science ®Google Scholar
• Chen J, Liang Q, Chen X, et al. Ceftazidime-avibactam versus polymyxin b in the challenge of carbapenem-resistant pseudomonas aeruginosa infection. Infect Drug Resist. 2022;15:655–667. doi:10.2147/IDR.S350976
   PubMed Web of Science ®Google Scholar